The Zurich Heart House would like to invite you to a special webinar on
A Breakthrough in HFpEF: Usage and Outcomes of SGLT2 Inhibitors
Date: Wednesday, November 10th, 2021, 17:00 – 18:30 CET
We are looking forward to meeting you during this webinar.
Thomas F. Lüscher, Zürich and London
Mattia Arrigo, Zürich
Otmar Pfister, Basel
Chairs in ZHH Studio: Mattia Arrigo, Zürich, Otmar Pfister, Basel and Thomas F. Lüscher, Zürich and London
|17:00||Welcome and introduction||Thomas F. Lüscher, Zurich/London|
|17:10||What is HFpEF? The ESC Guideline definition||Theresa McDonagh, London|
|17:25||Imaging patients with HFpEF: What criteria count?||Jeroen J. Bax, Leiden|
|17:40||EMPEROR-Preserved: SGLT2 inhibition in HFpEF||Michael Böhm, Homburg|
|17:55||SGLT2 inhibition in clinical practice: Which HF patients?||Otmar Pfister, Basel|
This programme is supported by Boehringer Ingelheim.
The scientific programme has not been influenced in any way by its sponsor.